REACH: Adherence to Dapivirine Vaginal Ring and Oral PrEP Among Adolescent Girls and Young Women in Africa

July 18-21, 2021; Virtual
Adherence to the dapivirine vaginal ring and oral PrEP was higher than anticipated over 12 months, with rates reaching 50% to 59% depending on the modality.
Format: Microsoft PowerPoint (.ppt)
File Size: 230 KB
Released: July 24, 2021

Acknowledgements

Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Produced in collaboration with
Supported by educational grants from
Gilead Sciences, Inc.
Janssen Therapeutics, Division of Janssen Products, LP
Merck Sharp & Dohme Corp.
ViiV Healthcare

Related Content

Clinical Care Options’ (CCO) commentary on patient education for people living with HIV during the COVID-19 pandemic

Sharon L. Walmsley, MSc, MD, FRCPC Released: September 22, 2021

From Dr. Eric S. Daar and Clinical Care Options (CCO), expert discussion on how new data from IAS 2021 expand our understanding of adverse events with specific ART regimens

Eric S. Daar, MD Physicians: maximum of 0.75 AMA PRA Category 1 Credits Registered Nurses: 0.75 Nursing contact hours Pharmacists: 0.75 contact hours (0.075 CEUs) Released: September 22, 2021 Expired: September 21, 2022

From Dr. Eric Daar and CCO, slides covering new data from IAS 2021 expanding our understanding of the adverse event profiles of specific ART regimens

Eric S. Daar, MD Released: September 22, 2021

Dr Milena Murray and Clinical Care Options (CCO): ART-associated gestational weight gain, pregnancy effects, and the impact of baseline maternal weight

person default Milena Murray, PharmD, MSc, BCIDP, AAHIVP Released: September 21, 2021

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue